Skip to main content
Evidence Snapshot

Hexokinase HKDC1

CHEMBL1741200 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T00:13:36Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1741200
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Hexokinase HKDC1 as ChEMBL target CHEMBL1741200, mapped to UniProt Q2TB90. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Hexokinase HKDC1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1741200
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q2TB90
Hexokinase HKDC1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Hexokinase HKDC1 matters

As of 2026-09-14

Hexokinase HKDC1 is reviewed as Hexokinase HKDC1 (UniProt Q2TB90); the current evidence base includes 1 approved drug, 438 compounds, and 7 assays, with lead potency reaching pChEMBL 6.7.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 438 compounds, and 7 assays for this target. The dominant activity type is IC50. CHEMBL1713955 is the current potency anchor at pChEMBL 6.7.

Use CHEMBL1713955 as the tractability anchor when discussing potency (pChEMBL 6.7).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 6.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Hexokinase HKDC1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q2TB90, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

438
Total Compounds
7
Total Assays
1
Approved Drugs
IC50: 572.0, EC50: 104.0, KD: 1.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1713955
 6.7 EC50 —
No preferred name
CHEMBL1725990
 6.2 EC50 —
No preferred name
CHEMBL1454614
 6.0 IC50 —
No preferred name
CHEMBL1395907
 5.9 IC50 —
No preferred name
CHEMBL1728280
 5.8 IC50 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T00:13:36Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1741200